Chronic myelogenous leukemia (CML) is a malignant disorder of the hematopoietic stem cell characterized by the BCR-ABL oncogene. We examined gene expression profiles of highly enriched CD34 þ hematopoietic stem and progenitor cells from patients with CML in chronic phase using cDNA arrays covering 1.185 genes. Comparing CML CD34 þ cells with normal CD34 þ cells, we found 158 genes which were significantly differentially expressed. Gene expression patterns reflected BCR-ABLinduced functional alterations such as increased cell-cycle and proteasome activity. Detoxification enzymes and DNA repair proteins were downregulated in CML CD34 þ cells, which might contribute to genetic instability. Decreased expression of junction plakoglobulin and CXC chemokine receptor 4 (CXCR-4) might facilitate the release of immature precursors from bone marrow in CML. GATA-2 was upregulated in CML CD34 þ cells, suggesting an increased self-renewal in comparison with normal CD34 þ cells. Moreover, we found upregulation of the proto-oncogene SKI and of receptors for neuromediators such as opioid l1 receptor, GABA B receptor, adenosine A1 receptor, orexin 1 and 2 receptors and corticotropine-releasing hormone receptor. Treatment of CML progenitor cells with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) resulted in a dose-dependent significant inhibition of clonogenic growth by 40% at a concentration of 10 À5 M, which could be reversed by the equimolar addition of the receptor agonist 2-chloro-N6-cyclopentyladenosine (Po0.05). The incubation of normal progenitor cells with DPCPX resulted in an inhibition of clonogenic growth to a significantly lesser extent in comparison with CML cells (Po0.05), suggesting that the adenosine A1 receptor is of functional relevance in CML hematopoietic progenitor cells.
Chronic myelogenous leukemia (CML) is a malignant disorder of the hematopoietic stem cell characterized by the BCR-ABL oncogene. We examined gene expression profiles of highly enriched CD34 þ hematopoietic stem and progenitor cells from patients with CML in chronic phase using cDNA arrays covering 1.185 genes. Comparing CML CD34 þ cells with normal CD34 þ cells, we found 158 genes which were significantly differentially expressed. Gene expression patterns reflected BCR-ABLinduced functional alterations such as increased cell-cycle and proteasome activity. Detoxification enzymes and DNA repair proteins were downregulated in CML CD34 þ cells, which might contribute to genetic instability. Decreased expression of junction plakoglobulin and CXC chemokine receptor 4 (CXCR-4) might facilitate the release of immature precursors from bone marrow in CML. GATA-2 was upregulated in CML CD34 þ cells, suggesting an increased self-renewal in comparison with normal CD34 þ cells. Moreover, we found upregulation of the proto-oncogene SKI and of receptors for neuromediators such as opioid l1 receptor, GABA B receptor, adenosine A1 receptor, orexin 1 and 2 receptors and corticotropine-releasing hormone receptor. Treatment of CML progenitor cells with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) resulted in a dose-dependent significant inhibition of clonogenic growth by 40% at a concentration of 10 À5 M, which could be reversed by the equimolar addition of the receptor agonist 2-chloro-N6-cyclopentyladenosine (Po0.05). The incubation of normal progenitor cells with DPCPX resulted in an inhibition of clonogenic growth to a significantly lesser extent in comparison with CML cells (Po0.05), suggesting that the adenosine A1 receptor is ofIntroduction Hematopoietic stem cells are characterized by the capability of self-renewal and differentiation into the entire spectrum of blood cells. Knowledge gained from stem cell biology can also give novel insights into cancer research. Due to their life-long persistence and selfrenewal capacity, stem cells have a high probability to accumulate mutations that eventually result in malignant transformation. In addition, stem cells and malignant cells share several features such as the ability to self-renew, similar mechanisms involved in migration and mechanisms for prevention of cellular aging such as telomerase expression (Passegue et al., 2003; Hope et al., 2004) .
The best-studied malignant stem cell disorder is chronic myelogenous leukemia (CML), which is characterized by a clonal expansion of hematopoietic progenitor cells (Faderl et al., 1999) . In 95% of patients a specific chromosomal translocation between chromosomes 9 and 22 is found, which results in the formation of the BCR-ABL fusion gene. The BCR-ABL protein has an elevated tyrosine kinase activity and plays a central role in the pathophysiology of the disease (Daley et al., 1990; Lugo et al., 1990) . Different mechanisms have been shown to be involved in the malignant transformation by BCR-ABL (Deininger et al., 2000) . The fusion oncoprotein activates mitogenic signalling pathways such as the RAS and mitogen-activated protein kinase pathway and protects CML cells from apoptosis. In addition, BCR-ABL induces adhesive and cytoskeletal abnormalities, which might facilitate the release of progenitors from the bone marrow (BM).
Large-scale gene expression analyses of leukemic cells from patients with Ph þ CML have been used to investigate a genomic profile associated with response to therapy with the tyrosine kinase inhibitor imatinib (McLean et al., 2004) and have broadened the knowledge about alterations of gene expression in BCR-ABLpositive cells in comparison with normal cells (Ohmine et al., 2001; Nowicki et al., 2003) . While Ohmine and coworkers examined CD133 þ hematopoietic progenitor cells in the study of Nowicki and co-workers mononuclear CML cells were used. However, mononuclear cells are a heterogenous cell population consisting of a broad spectrum of partially and completely differentiated cell types. Therefore, the expression pattern might only reflect the different proportions of the leukocyte subtypes in normal and CML mononuclear cells (Szaniszlo et al., 2004) . In order to compare similar cell subsets, to analyse a more homogenous cell population and to examine cells which are closer to the cell of origin in CML, we examined highly enriched CD34 þ hematopoietic stem and progenitor cells. By means of cDNA array technology, hierarchical cluster analysis, quantitative real-time RT-PCR, and flow cytometry, we identified a distinct gene expression pattern of malignant CD34 þ cells from patients with untreated newly diagnosed CML. We found numerous differentially expressed genes and demonstrated the functional role of the adenosine A1 receptor for the clonogenic growth of leukemic progenitor cells.
Results

Gene expression profiles of BM-CD34 þ cells in CML
Gene expression profiles of highly enriched CD34 þ cells from the BM of five patients with untreated CML in chronic phase were compared with those of 10 healthy donors (HD) using cDNA arrays covering 1185 defined genes. A total of 158 genes of different functional groups were significantly differentially expressed in CML CD34 þ cells (Po0.01), with 55 of them upregulated and 100 downregulated in CML (Figure 1 ). Complete expression data are shown in the Supplementary table available at Oncogene's website. First, we looked at genes which are known to be involved in the BCR-ABL signal transduction pathway. Several proteins downstream of BCR-ABL such as members of the RAS family and JAK2 were 2-7-fold upregulated in CML. On the other hand, the serinethreonine kinase AKT, which is part of the BCR-ABLactivated PI3 kinase pathway, showed a 2.4-fold reduced expression in CML CD34 þ cells.
In addition, the expression pattern reflected and explained the functional characteristics of CML progenitor cells on a molecular level, such as increased proliferation activity, release of immature precursors from BM or acquisition of secondary chromosomal abnormalities resulting in transformation into blast crisis. Several genes known to increase cell-cycle progression and replication such as prefoldin 4, several cyclins, cell division cycle 25C, cyclin-dependent kinase 4, interferon-inducible RNA-dependent protein kinase, 14-3-3 protein beta, and telomeric repeat-binding factor were significantly upregulated 1.4-10-fold in CML CD34 þ cells. On the other hand, expression of the cell-cycle inhibitors cyclin-dependent kinase inhibitors 1A and 2D were 2-3-fold greater in normal CD34 þ cells than in CML CD34 þ cells.
Looking at apoptosis-related genes, we found the antiapoptotic gene defender against cell death 1 to be 2.6-fold upregulated in CML and the proapoptotic genes caspase 2 and death-associated protein kinase 1 to be downregulated.
Examining genes involved in adhesion, we found a heterogenous expression pattern. The two subunits of the a4b1 integrin (VLA-4) were three-fold upregulated, whereas the b3 integrin subunit, intercellular adhesion molecule 1, sialophorin, and junction plakoglobin (JUP) were downregulated between 1.7-and 4.3-fold.
At present, the mechanisms underlying the transformation of BCR-ABL-positive cells into blast crisis are not known. A genetic instability is presumed as the basis for accumulation of mutations. Our expression data support this view since several detoxification enzymes and genes involved in DNA repair such as microsomal glutathione S-transferase, glutathione peroxidase 1, glutathione reductase, cytosolic superoxide dismutase, mutL homolog 1, RAD23A, ATP-dependent DNA ligase 1, and the DNA excision repair proteins ERCC1, ERCC3, and ERCC5 were significantly 2-4.4-fold lower expressed in CML CD34 þ cells compared with normal CD34 þ cells.
We also found differential expression of genes which might be suitable for targeted therapy. For example, three proteasome subunits were 3-4-fold overexpressed in CML, whereas the proteasome inhibitor subunit 1 was 1.4-fold downregulated.
Moreover, we found a distinct expression pattern of growth factors, cytokines, chemokines and their receptors in CML CD34 þ cells. Only one was upregulated in CML (small inducible cytokine subfamily E1, 3.6-fold), whereas 17 genes were significantly lower expressed in CML, including the cytokines and growth factors macrophage colony-stimulating factor, platelet-derived growth factor, and interleukin 10, as well as the neuromedin B receptor, the granulocyte colony-stimulating factor receptor, and the CXC chemokine receptor 4 (CXCR-4).
Looking at genes encoding proteins involved in transcription, zinc-finger proteins 9, 148, and 162, positive cofactor 4, hypoxia-inducible factor 1, and GATA-2 were upregulated in CML CD34 þ cells, and immediate early protein, DNA-binding protein TAX-REB302, E2F transcription factor 1, interferon regulatory factor, and myeloid cell nuclear differentiation antigen were downregulated in comparison to normal CD34 þ cells. We also examined proto-oncogenes and found most of them to be downregulated in CML CD34 þ cells. The proto-oncogene SKI was ninefold higher expressed in CML CD34 þ cells, whereas MYB-related protein B, JUN-D, FOS, ETS variant gene 6 (TEL protooncogene), and nonmetastatic cells 2 protein were downregulated between 2.1-and sixfold in comparison with normal CD34 þ cells.
Corroboration by quantitative real-time PCR
To corroborate some of the data obtained by cDNA arrays, expression of seven genes in CML CD34 þ cells and normal BM CD34 þ cells was examined by quantitative real-time RT-PCR using either LightCycler or TaqMan Technology. RT-PCR confirmed that JUP, tripeptidyl-peptidase (CLN2), defender against cell death 1 (DAD1), splicing factor 1 (SF162), SKI, 14-3-3 beta protein (YWHAB), and proteasome subunit atype 3 (PSMA3) were differentially expressed ( Figure 2 ).
Comparison of expression profiles between BM and peripheral blood (PB) CML CD34 þ cells and hierarchical cluster analysis
In a recent study, we have shown significant differences between the molecular phenotypes of BM-derived and circulating normal CD34 þ cells . Therefore, we asked whether CML CD34 þ cells circulating in PB have also different expression patterns in comparison with CD34 þ cells residing in the BM. In an intraindividual comparison of gene expression profiles of CD34 þ cells from the BM and PB of three patients with CML, no gene was found to be significantly differentially expressed in both compartments (data not shown).
In order to evaluate the heterogeneity of the cell samples and to demonstrate a characteristic expression pattern of CML CD34 þ cells in comparison with normal CD34 þ cells either from BM or from PB, a hierarchical cluster analysis was performed using an average linkage clustering algorithm. We included five samples of CML CD34 þ cells from BM, three samples of CML CD34 þ cells from PB, 10 samples of normal BM, and 12 samples of normal PB CD34 þ cells into the analysis. We identified three distinguishable array clusters: (1) a homogenous group of CML CD34 þ cells, independent of whether they were obtained from BM or PB, (2) the group of normal BM CD34 þ cells, and (3) the group of normal PB CD34 þ cells (Figure 3 ). The dendrogram shows that CML CD34 þ cells were more similar to normal CD34 þ cells from BM than from PB.
Expression of G protein-coupled neurobiological receptors
Recently, we have shown that genes primarily expressed in the nervous system may also be expressed in normal human CD34 þ cells (Steidl et al., 2004) . This finding prompted us to examine our CML CD34 þ cells with regard to the expression of genes involved in neurobiological functions. Out of the 56 neurobiological genes covered by our cDNA array, we found the opioid m1 and the adenosine A1 receptors, as well as the chloride channel 1A, to be 3-7-fold upregulated, and neurotrophin 3 to be twofold downregulated in CML CD34 þ cells. Next, we focused on the expression of G proteincoupled receptors for neuromediators on malignant CD34 þ hematopoietic progenitor cells in CML using indirect immunofluorescence analysis. We corroborated the differential mRNA expression of the adenosine A1 and the opioid m1 receptors also on the protein level, showing a 1.9-and 1.8-fold higher expression of those receptors in CML, respectively (Po0.05) (Figures 4 and  5) . Moreover, the GABA B receptor, the serotonine 1F receptor as well as the receptors for the hypothalamic peptides corticotropine-releasing hormone (CRH) and orexin were 1.8-2.2-fold upregulated in CD34 þ cells from patients with CML in chronic phase in comparison to normal CD34 þ cells, as shown by flow cytometry on single cells (Po0.05) (Figures 4 and 5) . Though the adenosine A2B receptor and the opioid k1 receptor were expressed in CML CD34 þ cells, a significant higher expression in comparison to normal CD34 þ cells could not be demonstrated.
Since we have previously shown that the expression of those receptors on normal CD34 þ cells depends on the coexpression of CD38 (Steidl et al., 2004) , we assessed the proportions of CD34 þ cells with low or high CD38 expression. Comparing CML CD34 þ cells with normal CD34 þ cells, we found a similar proportion of CD38 low expressing cells in both groups (4.26% (mean) vs 4.33% (mean)), indicating that differential expression of G protein-coupled receptors is not the result of a different composition of the CD34 þ cell population with regard to maturation state.
Clonogenic growth following modulation of receptor activity
For assessment of the functional role of opioid m1 and adenosine A1 receptors, mononuclear cells from the BM of patients with CML were subjected to clonogenic methylcellulose assays in the presence or absence of specific agonists or antagonists of the respective receptor. Incubation of cells with the agonist DAMGO or the antagonist Naloxone of the opioid m1 receptor did not influence clonogenic growth of malignant progenitor cells (Figure 6a ). On the other hand, incubation of cells with the specific adenosine A1 receptor antagonist DPCPX resulted in significant dose-dependent inhibitions of growth of CFU-GM by 40 and 47%, as well as of BFU-E by 25 and 37% using concentrations of 10 À5 and 10 À4 M, respectively (Figure 6b ). The effect of the antagonist at 10 À5 M could be significantly reversed by the equimolar addition of the selective agonist CCPA (Po0.01 for CFU-GM, Po0.05 for BFU-E). The incubation with agonist alone had no effect.
In comparison with leukemic progenitor cells, clonogenic growth of normal hematopoietic progenitor cells was less inhibited as incubation with the adenosine A1 receptor antagonist at a concentration of 10 À5 M resulted in a reduction of CFU-GM formation of 26%, whereas BFU-E formation was not changed (Figure 6c ). The reversal of the antagonist-induced effect on normal CFU-GM by equimolar addition of agonist was not significant (P ¼ 0.12). Therefore, the effect of DPCPX on the clonogenic growth of normal CFU-GM might be unspecific. Comparing the degree of inhibition of DPCPX-treated (10 À5 M) normal and CML progenitor cells by t-test for unpaired samples, we found a significant higher inhibition of CFU-GM as well as of BFU-E growth in CML (Po0.05).
Discussion
In this study, we provide for the first time gene expression profiles of highly enriched CD34 þ hematopoietic stem and progenitor cells from patients with CML in chronic phase and show a characteristic gene expression pattern in comparison to normal CD34 þ cells. In previous studies, gene expression analyses were performed using BCR-ABL-positive mononuclear cells of patients with CML in chronic phase (Nowicki et al., 2003) . An important limitation of this approach was that a very heterogenous population of CML cells was used, consisting of a broad spectrum of different precursors. This cell population was compared with fully differentiated normal control cells. In another study, CD133 was used to enrich hematopoietic progenitor cells from patients with CML for gene expression analyses (Ohmine et al., 2001) . This study focused on the identification of molecular events associated with disease progression. In our study, we used highly enriched CD34 þ cells which still represent a heterogenous population containing stem and progenitor cells. However, CD34 þ cells are closer to the cell of origin of the leukemic clone than mononuclear cells. Moreover, we showed by two-color immunofluorescence analysis of CD38 coexpression that the cellular composition with regard to maturation state was similar in the leukemic and control CD34 þ cell samples. genes involved in cell-cycle progression were significantly upregulated in CML, whereas out of the group of apoptosis-related genes only few were differentially Figure 3 Hierarchical cluster analysis. The 30 samples subjected to cluster analysis were derived from CML CD34 þ cells from BM (CML1-5), CML CD34 þ cells from PB (CML6-8), normal CD34 þ cells from BM (BM1-10) or normal CD34 þ cells from PB (PB1-12). Cluster analysis was performed on the basis of 60 genes which were at least 1.4-fold differentially expressed comparing CML CD34 þ cells from BM either with normal CD34 þ cells from BM or with normal CD34 þ cells from PB. Gene symbols are given according to HUGO nomenclature. Data are displayed by a color code. Red fields indicate higher values than the median, green fields indicate lower values than the median. The dendrogram visualizes the degree of similarity of the different subgroups by the branch length Figure 4 Protein expression of G protein-coupled receptors on normal and malignant CD34 þ cells. Highly enriched CD34 þ cells from the BM of a healthy volunteer and of a patient with CML were assessed by two-color immunofluorescence analysis using a FITCconjugated anti-CD34 antibody and receptor-specific antibodies detected by a rhodamine-conjugated secondary antibody. The cutoff level for receptor expression was set according to the isotype control and is indicated by a line. The proportion of positive cells is given in each histogram. A representative experiment is shown Molecular phenotype of CML CD34 þ cells R Kronenwett et al expressed. Our findings support the view that enhanced cell-cycle activation of CML CD34 þ cells (Cortez et al., 1997) rather than decreased apoptosis (Bedi et al., 1994) is responsible for the pronounced expansion of leukemic progenitors (Gora-Tybor et al., 1998; Traycoff et al., 1998) .
An interesting finding is the upregulation of proteasome subunits in CML. Recent reports have shown that BCR-ABL induces a proteasome-mediated degradation of inhibitory proteins in Ph-positive aggressive leukemias (Dai et al., 1998; Jonuleit et al., 2000) . The Figure 5 Differential expression of G protein-coupled receptors in CML CD34 þ cells. Summary of protein expression data of G protein-coupled receptors on BMÀCD34 þ cells from three healthy volunteers and three patients with CML is shown. Cells were stained as described in Figure 4 . For each sample, mean fluorescence intensities (MFI) of cells stained with isotype-control antibody as well as of cells stained with the respective specific antibody were assessed. MFI of the sample stained with specific antibody was divided by the MFI of the respective isotype control antibody-stained sample resulting in the relative expression level (fold increase over control antibody). Mean values and standard deviations of relative expression levels of normal (white bars) and CML (gray bars) CD34 þ cells are displayed. Statistically significant higher expression in CML is indicated by asterisk (Po0.05) Figure 6 Clonogenic growth of CML and normal progenitor cells following receptor modulation. Mononuclear cells of BM of patients with CML and healthy volunteers were examined by semisolid methylcellulose clonogenic assays in the presence or absence of receptor agonists and/or antagonists. BFU-E (gray) and CFU-GM (white bars) were counted after two weeks. Mean values and standard deviations are shown. (a) MNC from three patients with CML were examined using the opioid m1 receptor agonist DAMGO and/or antagonist naloxone. (b) MNC of patients with CML were incubated with the adenosine A1 receptor agonist CCPA and/or antagonist DPCPX at concentrations of 10
The degree of inhibition was referred to the samples incubated with DMSO alone, which was the diluent for CCPA and DPCPX. Combined administration of CCPA and DPCPX at a concentration of 10 À4 M as well as the respective amount of diluent alone resulted in a complete inhibition of clonogenic growth due to the high concentration of DMSO in the culture medium (20 ml/ml). Statistically significant inhibition of DPCPX referring to the DMSO control is indicated by a cross (Po0.05) or asterisk (Po0.001). Statistically significant reversal of DPCPX effects (10 À5 M) on CFU-GM and BFU-E growth by equimolar addition of CCPA is indicated, with the respective Pvalue by brackets. (c) MNC of three healthy volunteers were incubated with the adenosine A1 receptor agonist and/or antagonist at concentrations of 10 À6 and 10 À5 M. Statistically significant inhibition of DPCPX referring to the DMSO control is indicated by a cross (Po0.05). Reversal of DPCPX-induced inhibition of CFU-GM growth could not be shown with sufficient statistical significance. P-value is indicated Molecular phenotype of CML CD34 þ cells R Kronenwett et al overexpression of proteasome subunits in CML suggests that proteasome-mediated degradation also plays a role in chronic phase CML, which might have therapeutic implications. This is supported by the finding that proteasome inhibitors induced apoptosis in BCR-ABLpositive cells and had greater inhibitory effects on clonogenic growth of CML progenitor cells than normal CD34 þ cells (Soligo et al., 2001; Yu et al., 2003) . One reason for abnormal proliferation and egress of progenitor cells and partially differentiated myeloid precursor cells from BM into the blood might be a defect of adhesive properties of CML cells (Gordon et al., 1987; Verfaillie et al., 1997) . Interestingly, we showed that JUP is downregulated in CML. JUP is part of the cellular cadherin-catenin complex and plays a role in cellular adhesion (Ben Ze'ev and Geiger, 1998) . Its downregulation could be responsible for the adhesive abnormalities of CML cells. Another interesting finding is decreased expression of the chemokine receptor CXCR-4 on CML CD34 þ cells. CXCR-4 plays a role in mobilization and homing of normal CD34 þ cells (Mohle et al., 1998) . Circulating CD34 þ cells expressed CXCR-4 at a lower level than sedentary CD34 þ cells , and antagonists against the chemokine receptor resulted in mobilization of hematopoietic progenitor cells (Liles et al., 2003; Devine et al., 2004) . Therefore, the reduced CXCR-4 expression in CML CD34 þ cells might contribute to the release of malignant progenitor cells from BM. Surprisingly, we were unable to detect differentially expressed genes when comparing CML CD34 þ cells from BM with those from PB, although we and others had observed distinct molecular phenotypes when examining normal CD34 þ cells from BM and PB (Graf et al., 2001; Steidl et al., 2002; Ng et al., 2004) . In normal BM CD34 þ cells, a significantly higher expression of genes governing cell-cycle progression was found in comparison to PB CD34 þ cells. Therefore, the physiological switch from a more proliferating to a quiescent phenotype, which was found during egress of normal CD34 þ cells from BM to PB might be disturbed in chronic phase CML.
Oncogenes and tumor suppressor genes are another interesting group of genes with respect to malignant transformation. We found a significant downregulation of ETS variant gene 6 (ETV6; TEL oncogene), JUN-D, and FOS in CML progenitor cells. ETV6 is essential for the establishment of hematopoiesis of all lineages in the BM (Wang et al., 1998) . Moreover, ETV6 is involved in chromosomal translocations associated with hematological malignancies as, for example, the ETV6-AML1 gene fusion in t(12;21)-positive childhood acute lymphoblastic leukemia (ALL) (Wlodarska et al., 1996) . Therefore, downregulation of ETV6 in hematopoietic progenitor cells could be involved in the molecular pathogenesis of CML. JUN-D antagonizes the positive regulatory effects of c-JUN on cell cycle and is expressed preferentially in quiescent cells (Musti et al., 1996; Liebermann and Hoffman, 1998) . In the same line, FOS plays a role in growth suppression and apoptosis in many cell types (Liebermann and Hoffman, 1998) . Therefore, downregulation of JUN-D and FOS might be responsible for increased proliferation of CML progenitor cells.
In our study, we show for the first time that the SKI proto-oncogene is upregulated in CML CD34 þ cells, suggesting a pathophysiological role in CML. SKI regulates terminal differentiation of skeletal muscle (Namciu et al., 1995) , and a viral homolog of SKI induced the proliferation of myeloid-erythroid multipotential progenitor cells from avian BM (Dahl et al., 1998) . The SKI-induced effects in hematopoietic progenitor cells seem to be caused in part by repression of the retinoic acid receptor (RAR) signaling pathway, since high concentrations of RARa-specific ligands could revert transformation of avian progenitor cells by SKI. Therefore, SKI or RARa might be interesting candidates for targeted therapy in CML.
The mechanisms underlying transformation of chronic phase CML into blast crisis are still poorly understood. A presumed BCR-ABL-induced genetic instability might result in somatic mutations such as loss of p53 function, which leads to blastic transformation (Honda et al., 2000) . Supporting this view, we found several genes encoding detoxification enzymes and proteins responsible for DNA repair to be downregulated in chronic phase CML CD34 þ cells in comparison to normal CD34 þ cells. Those genes include glutathione S-transferases, reduced expression of which contributes to an increased genetic instability in AML, for example (Haase et al., 2002) . Together with a decreased expression of genes involved in DNA repair, such as DNA excision repair proteins, this might facilitate further mutations in CML CD34 þ cells, which are often encountered after cytotoxic therapy (Izumi et al., 1996) or in advanced phases of CML (Deininger et al., 2000) .
Further, we were interested in the expression pattern of genes characteristic for hematopoietic stem cells. Genes playing a role in self-renewal and differentiation covered by our array were GATA-2, GATA-3, and C/ EBPa (Zhu and Emerson, 2002; Passegue et al., 2003; Steidl et al., 2003) . GATA-2, an essential transcription factor for self-renewal and maintainance of stem cells in an undifferentiated stage, was 1.8-fold upregulated in CML CD34 þ cells. On the other hand, GATA-3 and C/EBPa, transcription factors governing lymphoid and myeloid lineage commitment decisions, respectively, were not expressed at all in CML CD34 þ cells. These findings suggest that malignant hematopoietic stem cells in CML have a greater ability to self-renew in comparison with normal CD34 þ cells.
Finally, in this study, we show for the first time that leukemic hematopoietic progenitor cells expressed several G protein-coupled receptors which were primarily assigned to the nervous system, such as GABA B receptor, opioid m1 and k1 receptors, serotonine 1F receptor, adenosine A1 and A2B receptors, and receptors of the hypothalamic peptides corticotropin-releasing hormone (CRH) and orexins. In a previous study, our group has shown that normal primary human CD34 þ cells express functionally active receptors of neuromediators (Steidl et al., 2004) . However, the functional relevance of those receptors for normal and malignant hematopoiesis is not known so far. Since seven of the nine assessed receptors are significantly upregulated in leukemic CD34 þ cells in comparison with normal CD34 þ cells, one might speculate that they play a pathophysiological role in CML. As assessed by two-color immunofluorescence analysis, the proportion of more immature CD38-negative cells was similar in CML and normal CD34 þ cells. Therefore, differential expression of G protein-coupled receptors due to different composition of the CD34 þ cell populations is unlikely. We assessed the functional role of two of those G protein-coupled receptors with respect to clonogenic growth by treating cells with specific agonists and antagonists. Incubation of CML mononuclear cells with DAMGO, a selective agonist of the opioid m1 receptor, or with the antagonist Naloxone had no effect on the clonogenic growth of lineage-committed progenitor cells. This is surprising since in a previous study an increased proliferation of granulocyte-macrophage, erythroid and multipotential progenitor cells in BM and spleen was found in opioid m1 receptor-deficient mice, suggesting a negative regulatory influence on normal hematopoiesis (Tian et al., 1997) . Incubation of CML mononuclear cells with a specific antagonist of the adenosine A1 receptor resulted in a significant dosedependent inhibition of clonogenic growth of both, CFU-GM and BFU-E, suggesting a role in proliferation and differentiation of myelomonocytic as well as erythoid lineage-committed progenitor cells in CML. This is in line with recent data showing that extracellular adenosine enhances cell cycling of hematopoietic progenitors (Pospisil et al., 2001) . The incubation of normal mononuclear cells with the adenosine A1 receptor antagonist resulted in an inhibition of CFU-GM formation to a significantly lesser extent in comparison with CML mononuclear cells and did not affect growth of normal BFU-E at all. This suggests that the upregulation of the adenosine A1 receptor in leukemic CD34 þ cells, although rather mild, is of functional significance in CML. The adenosine A1 receptor might therefore be a target for therapeutic approaches with specific receptor antagonists.
In conclusion, our data provide a gene expression profile of primary CD34 þ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Gene expression patterns reflected and explained the functional properties of leukemic cells on a molecular level. Furthermore, we identified genes such as the SKI proto-oncogene or receptors of neuromediators which might be of functional relevance in CML.
Materials and methods
Cells
After informed consent, BM mononuclear cells and PB mononuclear cells were obtained by density centrifugation from patients with untreated newly diagnosed Ph þ CML in chronic phase. Patients' characteristics are given in Table 1 . All patients had 100% Philadelphia chromosome-positive metaphases in standard BM cytogenetics. Normal BM cells from 10 healthy volunteers and PB mononuclear cells from 12 healthy volunteers were obtained as described previously .
CD34 þ cells were positively selected using the midiMACS immunomagnetic separation system (Miltenyi Biotec, Bergisch Gladbach, Germany) as described previously . Purities of CML CD34 þ cells are given in Table 1 . Purities of normal CD34 þ cells ranged between 90 and 99%.
RNA isolation, reverse transcription, and hybridization to nylon cDNA arrays Isolation of total RNA from 2 Â 10 5 to 2.6 Â 10 7. CD34 þ cells was performed with the RNeasy Mini Kit (Qiagen AG, Hilden, Germany) according to the manufacturer's Age, PB counts (leukocytes, thrombocytes, hemoglobin), BCR-ABL transcript levels (BCR-ABL/G6PDH ratio) and purity of enriched CD34+ cells is given for each patient included in this study. BCR-ABL/G6PDH ratio was assessed as previously described (Neumann et al., 2003) . For clonogenic assays, no CD34+ cell selection was performed (n.p.)
Molecular phenotype of CML CD34 þ cells R Kronenwett et al instructions. Atlas Human 1.2 I arrays (BD Biosciences Clontech, Heidelberg, Germany) were used for hybridization experiments. Between 600 ng and 5 mg RNA were reversetranscribed and radioactively labeled as described previously .
Quantification, normalization, and statistical analysis
Phosphorimager screens were scanned using a Phosphorimager (Fuji FLA-3000, FujiFilm) controlled by the BAS-Reader 3.01. Software (Raytest, Straubenhardt, Germany). Dot intensities were measured with the Aida Image Analyzer Software (Raytest, Straubenhardt, Germany). After background subtraction, raw data were normalized using the median intensity of the 20% highest expressed genes and expressed as the ratio (dot intensity)/(median intensity). To compare the CD34 þ cell samples of patients with CML with the samples of HD, for each gene the median values of the CML and the HD group were calculated and the CML median was divided by the HD median obtaining the ratio CML/HD. For calculation of significant differential expression, the Mann-Whitney u-test was used. P-values smaller than 0.01 were accepted as statistically significant. Hierarchical cluster analysis was performed by the 'hclust' function of the statistical scripting language 'R' integrated into the Bioconductor project (http://www.bioconductor.org/) using an average linkage clustering algorithm.
Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR)
Corroboration of RNA expression was performed by real-time RT-PCR using either the LightCycler s technology (Roche Molecular Biochemicals, Mannheim, Germany) as described or the ABI PRISM s 7900HT Sequence Detection System Instrument (Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany). Total RNA was extracted using the 'Absolute RNA Microprep' system (Stratagene, La Jolla, CA, USA) and was reverse-transcribed as described previously . GAPDH mRNA served as external control for relative quantification. LightCycler PCR was performed using the LightCyclerFastStart DNA Master SYBR Green kit (Roche Molecular Biochemicals). The following primers were used: GAPDH: 5 0 -TCCATGACAACTTTGGTATCG-3 0 , 5 0 -GTCGCTGTTGA AGTCAGAGGA-3 0 ; JUP: 5 0 -GTCAAGGCAACCATCG-3 0 , 5 0 -CTCCTCCATCCTCACA-3 0 ; tripeptidyl-peptidase: 5 0 -TTC ATACCAGGAGGAAGC-3 0 , 5 0 -CCTTGGGTTGAGAAA GC-3 0 ; defender against cell death 1: 5 0 -TAGCGGTTTGCCT GAG-3 0 , 5 0 -GTTGTTCTGACACACAGT-3 0 ; SKI: 5 0 -CTTC CAATAAGAGCCTG-3 0 , 5 0 -ATGAGGTAAAGGACGG-3 0 ; 14-3-3 beta protein: 5 0 -GACAACAAACAAACCAC-3 0 , 5 0 -GTCCCTAAGTAACTGC-3 0 . Primers were designed using the 'LightCycler Probe Design' software 1.0 (Roche Molecular Biochemicals). The crossing points (CP) of real-time PCR curves were determined by the LightCycler 3.5 software using the second derivative maximum method. Relative gene expression levels were expressed as difference of CP values of target gene and GAPDH (DCP).
ABI PRISM s PCR was performed in a MicroAmp Optical 96-well Reaction Plate (Applera) according to the instructions of the manufacturer of the Assays-on-demand using an ABI PRISM s 7900HT Sequence Detector. The following Assayon-Demand Gene Expression Products (Applera) were used: proteasome subunit a-type 3 (Hs00160558_m1), splicing factor 1 (Hs00190309_m1), and GAPDH (Hs99999905_m1). Ct values were calculated by the ABI PRISM software and relative gene expression levels were expressed as the difference of CT values of target gene and GAPDH (DCT).
Immunofluorescence staining and flow cytometry
Immunomagnetically selected CD34 þ cells were stained with a fluorescein isothiocyanate-conjugated (FITC) monoclonal anti-CD34 antibody (clone 8G12, Becton Dickinson, Heidelberg, Germany) as described . Analysis of CD38 coexpression and detection of opioid m1 and k1 receptors, GABA B receptor, serotonin (5-HT) 1F receptor, adenosine A1 and A2B receptors, CRH receptor, and orexin receptors 1 and 2 by indirect immunofluorescence was performed as described (Steidl et al., 2004) .
Semisolid clonogenic assays
MNC from the BM of untreated patients with CML in chronic phase were seeded in semisolid ready-to-use methylcellulose growth medium containing stem cell factor, granulocytemacrophage colony-stimulating factor, granulocyte colonystimulating factor, interleukin-3, interleukin-6, erythropoietin (MethoCult H4436, StemCell Technology, Vancouver, Canada) at concentrations ranging between 1 Â 10 5 and 1 Â 10 6 cells/ ml with agonist DAMGO (Sigma, Taufkirchen, Germany) or antagonist Naloxone (DuPont, Bad Homburg, Germany) of the opioid m1 or agonist CCPA (Sigma) or antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine; Sigma) of the adenosine A1 receptors or with both (final concentrations of agonists and antagonists: 1 Â 10 À6 , 1 Â 10
À5
, and 1 Â 10 À4 M) as described previously (Kronenwett et al., 1998) . CCPA and DPCPX were dissolved with dimethyl sulfoxide (DMSO; Sigma) before use, resulting in a 10 À2 M stock solution. Colony numbers (colonyforming units granulocyte/macrophage (CFU-GM), burstforming units erythrocyte (BFU-E)) were counted after 2 weeks. For treatment of normal hematopoietic progenitor cells with CCPA and DPCPX, MNC from healthy volunteers were used in clonogenic assays at final concentrations of agonist or antagonist of 1 Â 10 À6 and 1 Â 10 À5 M.
Statistical analysis
For calculation of statistically significant differences between two groups in quantitative real-time RT-PCR, flow cytometry, and clonogenic assays, the t-test for unpaired or paired samples was used. A P-value o0.05 was considered to be statistically significant.
